Evaluating Gene Transfer Products for Gene Expression in Mouse Nasal Epithelium. (2004)

Jones, B. L., Sumner-Jones, S. G., Gill, D. R. & Hyde, S. C.

Journal of Cystic Fibrosis, 3, S29

Download   Back

As part of the UK Cystic Fibrosis Gene Therapy Consortium, we are aiming to identify gene transfer agents (GTA) that are candidates for delivery of CFTR to human airways. Typically, products identified from the literature or developed by members of the Consortium, including targeting peptides (e.g. HIV-TAT), lipids/liposomes (e.g. GL67) and polymers (e.g. JetPEITM), are tested in a series of assays, through which products can be evaluated systematically. The GTA are screened first in the mouse nose using a luciferase reporter gene to identify promising formulations; these are then taken through to our nPD (nasal potential difference) core facility where changes in conductance of nasal airway are measured in CF mice after treatment with a CFTR-encoding plasmid in the chosen formulation. The next stage is aerosolisation of the GTA in sheep lungs, which models the physical delivery of our chosen GTA, in anticipation of human clinical trials. The initial testing in the mouse nose involves the perfusion of 100?l of GTA into the left nostril of C57BL6 mice over 15'. Our studies are powered at 0.8-0.95 with n=6-8 per group. Luciferase and protein assays (with intra- and inter-assay variability <=10%) are combined to give activity in relative light units/mg protein. The GTA are tested in standardised conditions, including a dose response starting from the Maximum Feasible Dose (MFD) to one tenth of MFD. Additionally, various ratios of components can be tested. In the last 6 months, we have tested over 20 GTA. We anticipate being able to test 1-2 novel products per week. We will show examples of the iterative process required to optimise airway specific gene expression of a particular GTA prior to its progression to the next stage of evaluation.

Introductory Videos
Medical Futures Innovation Award 2011
Twitter Feed
About Us
Contact Us
Lab Events
Environemental Policy
About this Site

Google Site Search

Site Feedback Form

All Site Images



How the Consortium works/FAQs

Consortium Website

Centre for Molecular Medicine, Edinburgh
The Roslin Institute
Dep of Gene Therapy, Imperial



The Run-in Study

Single Dose Clinical Trial

Multi Dose Clinical Trial


Our Research

Non-viral Vector Development

Aerosol Mediated Gene Delivery

Viral Vector Development

Taqman Core Facility

Cystic Fibrosis

History of CF

Discovery of the CFTR Gene

CFTR Protein Structure

CFTR Function

CF Links


Gene Therapy

Introduction to Gene Therapy

Other CF Gene Therapy Groups

Why use Gene Therapy for CF

Target Cells for CF Gene Therapy

Barriers for CF Gene Therapy

Clinical Trials

Gene Therapy Successes

Gene Therapy Links




Papers in Journals

Conference Posters & Presentations

Book Chapters

D.Phil Theses



Gene Therapy Seminars


Directions & Venue